Back to Menu
1. Medical history and clinical symptom assessment
A detailed history is obtained regarding headache, visual symptoms, menstrual status, and changes in appearance, and signs of hormone hypersecretion or hypopituitarism are assessed as the primary diagnostic clues.
2. Endocrine hormone testing
Blood tests for prolactin, growth hormone, and other pituitary hormones are used to determine secretory function and tumor subtype, serving as core laboratory evidence.
3. Pituitary MRI
Non-contrast and contrast-enhanced MRI is the diagnostic “gold standard,” clearly defining tumor size, location, and its relationship to the optic apparatus.
4. Visual acuity and visual field testing
Routine visual acuity charts and perimetry provide objective quantification of optic pathway compression and help assess urgency for surgical intervention.
5. Histopathological examination
Postoperative pathology is the basis for definitive confirmation. Immunohistochemistry determines hormone lineage and supports evaluation of biological behavior.
6. Differential diagnostic workup
Differentiation from craniopharyngioma, meningioma, and other lesions may require dynamic endocrine testing, angiography, or specialized MRI sequences.
7. Genetic testing
Genetic testing is recommended for young patients, those with multiple lesions, or those with a family history to evaluate hereditary syndromes and guide family management.
8. Multidisciplinary team assessment
Collaboration among neurosurgery, endocrinology, radiology, and other specialties is required to ensure comprehensive diagnosis and optimize management strategies.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that although most pituitary adenomas are benign, hormonal abnormalities and mass effect can cause substantial impairment of vision, fertility, and other functions. Early diagnosis and precise intervention are pivotal. Patients with suspicious symptoms should seek medical evaluation promptly. With MDT-based collaboration and minimally invasive techniques, disease control can be achieved and patients can return to health.
1. Medical history and clinical symptom assessment
A detailed history is obtained regarding headache, visual symptoms, menstrual status, and changes in appearance, and signs of hormone hypersecretion or hypopituitarism are assessed as the primary diagnostic clues.
2. Endocrine hormone testing
Blood tests for prolactin, growth hormone, and other pituitary hormones are used to determine secretory function and tumor subtype, serving as core laboratory evidence.
3. Pituitary MRI
Non-contrast and contrast-enhanced MRI is the diagnostic “gold standard,” clearly defining tumor size, location, and its relationship to the optic apparatus.
4. Visual acuity and visual field testing
Routine visual acuity charts and perimetry provide objective quantification of optic pathway compression and help assess urgency for surgical intervention.
5. Histopathological examination
Postoperative pathology is the basis for definitive confirmation. Immunohistochemistry determines hormone lineage and supports evaluation of biological behavior.
6. Differential diagnostic workup
Differentiation from craniopharyngioma, meningioma, and other lesions may require dynamic endocrine testing, angiography, or specialized MRI sequences.
7. Genetic testing
Genetic testing is recommended for young patients, those with multiple lesions, or those with a family history to evaluate hereditary syndromes and guide family management.
8. Multidisciplinary team assessment
Collaboration among neurosurgery, endocrinology, radiology, and other specialties is required to ensure comprehensive diagnosis and optimize management strategies.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that although most pituitary adenomas are benign, hormonal abnormalities and mass effect can cause substantial impairment of vision, fertility, and other functions. Early diagnosis and precise intervention are pivotal. Patients with suspicious symptoms should seek medical evaluation promptly. With MDT-based collaboration and minimally invasive techniques, disease control can be achieved and patients can return to health.